|
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT ID : 04291105
Protocol Number : VYR-VSV2-203
Phase : 2
Location : Santa Monica, CA
|
Dr. O'Day
|
|
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
NCT ID : 03802123
Protocol Number : IAB-CD8-201
Phase : 2
Location : Santa Monica, CA
|
Dr. O'Day
|
|
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT ID : 03170960
Protocol Number : XL184-021
Phase : 1 and 2
Location : Santa Monica, CA
|
Dr. Twardowski
|
|
A Phase I Study of AGEN1181, an Fe-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer
NCT ID : 03860272
Protocol Number : C-800-01
Phase : 1
Location : Santa Monica, CA
|
Dr. O'Day
|
|
Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors
NCT ID : 03684785
Protocol Number : AST-008-102
Phase : 1b/2
Location : Santa Monica, CA
|
Dr. O'Day
|
|
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
NCT ID : 03633110
Protocol Number : GEN-009-101
Phase : 1 and 2
Location : Santa Monica, CA
|
Dr. Twardowski
|
